New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:24 EDTITMNInterMune upgraded to Outperform from Market Perform at Leerink
Leerink upgraded InterMune to Outperform saying data at the American Thoracic Society presents a strong case that favors the use Esbriet over Boehringer-Ingelheim's nintedanib in idiopathic pulmonary fibrosis. The firm keeps a $41 price target for shares.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ITMN news | >>
August 25, 2014
10:40 EDTITMNBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
10:00 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:11 EDTITMNOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTITMNRoche to hold a conference call
CEO Schwan and CFO Hippe discuss the acquisition of InterMune on a conference call to be held on August 25 at 9 am. Webcast Link
07:11 EDTITMNInterMune volatility expected to move on Roche acquiring for $8.3B
Subscribe for More Information
06:39 EDTITMNInterMune downgraded to Hold from Buy at Stifel
Roche (RHHBY) is buying InterMune (ITMN) in a deal valued at $8.3B, or $74 per a share.
August 24, 2014
20:27 EDTITMNRoche drops pursuit for remainder of Japan's Chugai, Bloomberg says
Subscribe for More Information
13:41 EDTITMNRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
August 21, 2014
10:14 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:22 EDTITMNInterMune downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded InterMune to Market Perform citing valuation.
August 20, 2014
05:53 EDTITMNStocks with implied volatility movement; NGD ITMN
Subscribe for More Information
August 14, 2014
10:05 EDTITMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adidas (ADDYY) downgraded to Neutral from Buy at Goldman... Fabrinet (FN) downgraded at B. Riley... Freeport McMoRan (FCX) downgraded at Stifel... Infosys (INFY) downgraded to Hold from Buy at Jefferies... InterMune (ITMN) downgraded to Neutral from Buy at Goldman... Jones Energy (JONE) downgraded to Neutral from Overweight at JPMorgan... LVMH Moet Hennessy (LVMUY) downgraded to Neutral from Buy at Goldman... Madison Square Garden (MSG) downgraded to Hold from Buy at Topeka... Qualys (QLYS) downgraded to Sector Perform from Outperform at RBC Capital... SeaWorld (SEAS) downgraded to Market Perform from Outperform at Wells Fargo... Theravance Biopharma (TBPH) downgraded to Underperform from Neutral at RW Baird... URS Corporation (URS) downgraded to Neutral from Buy at Sterne Agee... ViaSat (VSAT) downgraded to Perform from Outperform at Oppenheimer... Wynn Resorts (WYNN) downgraded to Hold from Buy at Gabelli.
09:11 EDTITMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
05:28 EDTITMNInterMune downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InterMune (ITMN) to Neutral citing valuation after the stock rallied on a Bloomberg report of takeover interest. Goldman continues to expect InterMune's Esbriet for orphan lung disease will receive FDA approval on or before the November 23 action date. The firm has a $49 price target for shares, which closed yesterday up 14% to $52.06.
August 13, 2014
16:19 EDTITMNOn The Fly: Closing Wrap
Subscribe for More Information
13:29 EDTITMNInterMune options active after Bloomberg report of takeover bids
Subscribe for More Information
13:13 EDTITMNInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
13:02 EDTITMNInterMune jumps 20% to $54.57 after Bloomberg report of takeover bids
Subscribe for More Information
13:01 EDTITMNInterMune working with banks on sale after bids, Bloomberg reports
Subscribe for More Information
13:00 EDTITMNInterMune received takeover bids from Sanofi, Roche, Bloomberg says
1 | 2 | all recent ITMN news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use